Followers | 3819 |
Posts | 239197 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
Tuesday, October 10, 2017 3:01:48 PM
Roka Bioscience (ROKA) surged 153% to their highest level in more than two months -- piercing their 50- and 100-day moving averages for the first time since April -- in the wake of a disclosure Edward Painter, CEO of A2A Pharmaceuticals, has acquired 340,000 shares of Roka, or 6.79%. "Edward Painter purchased shares with the intention of seeking a business combination with A2A Pharmaceuticals, a private biotechnology company," according to a regulatory statement. "He may sell shares or buy additional shares or change his purpose of transacting in the future." Roka sold substantially all of its assets in August to a subsidiary of Institute for Environmental Health for $17.5 million in cash, the initial step in a contemplated liquidation of the molecular diagnostics company.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM